Pat Fetaya joined Servier, a EU5.9B annual revenue France based pharmaceutical firm, in 2021 in its Boston US Headquarters as Head, US Business Development. In this role, he has accountability for developing strategies, assessing external opportunities, and executing acquisition, licensing, venture capital, and partnership transactions. 

Most recently, he led US Business development efforts for Sun Pharmaceuticals, where he was a key member of the team that built the firm’s Specialty Pharm business via key business development deals. Prior to that, he was a member of the Global Commercialization team at Bristol Myers Squibb, where he was recognized with the BMS President's Award for work in aligning Global and Regional product pre-launch processes. Earlier in his career, he worked in Business Development at Johnson and Johnson, where he developed growth strategies, closed over 30 transactions, and served as liaison to the Company's Asia-Pacific business development group.

Mr. Fetaya obtained an honor with distinction Masters in Engineering from the University of Pennsylvania, an MBA in Finance from Rutgers, and a BA in Chemistry. He is an active member of the Association for Corporate Growth NJ chapter.